×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
JNJ – johnson & johnson (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
JNJ
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/19
09:03 am
jnj
Model N Achieves ISO/IEC 27001 Certification, the Global Standard for Information Security [Yahoo! Finance]
Low
Report
Model N Achieves ISO/IEC 27001 Certification, the Global Standard for Information Security [Yahoo! Finance]
12/19
06:05 am
jnj
Why Is Johnson & Johnson (JNJ) Among the Best Dividend Stocks to Invest In? [Yahoo! Finance]
Low
Report
Why Is Johnson & Johnson (JNJ) Among the Best Dividend Stocks to Invest In? [Yahoo! Finance]
12/19
03:07 am
jnj
Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA [Yahoo! Finance]
Low
Report
Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA [Yahoo! Finance]
12/18
03:03 pm
jnj
Why Long-Form Entertainment Can Be A Content Marketer’s Biggest Gift: USPS’s Dear Santa Franchise [Forbes]
Low
Report
Why Long-Form Entertainment Can Be A Content Marketer’s Biggest Gift: USPS’s Dear Santa Franchise [Forbes]
12/18
11:08 am
jnj
Innovating With Purpose: Johnson & Johnson’s Mission To Develop Targeted Treatments For Autoantibody Diseases [Forbes]
Low
Report
Innovating With Purpose: Johnson & Johnson’s Mission To Develop Targeted Treatments For Autoantibody Diseases [Forbes]
12/18
09:45 am
jnj
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study [Yahoo! Finance]
Low
Report
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study [Yahoo! Finance]
12/18
04:01 am
jnj
Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA® (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transpl
Low
Report
Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA® (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transpl
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/12
05:28 pm
jnj
Form 4 JOHNSON & JOHNSON For: Dec 12 Filed by: WEINBERGER MARK A
Low
Report
Form 4 JOHNSON & JOHNSON For: Dec 12 Filed by: WEINBERGER MARK A
12/12
05:17 pm
jnj
Form 4 JOHNSON & JOHNSON For: Dec 10 Filed by: Woods Eugene A.
Low
Report
Form 4 JOHNSON & JOHNSON For: Dec 10 Filed by: Woods Eugene A.
12/12
05:10 pm
jnj
Form 4 JOHNSON & JOHNSON For: Dec 10 Filed by: HEWSON MARILLYN A
Low
Report
Form 4 JOHNSON & JOHNSON For: Dec 10 Filed by: HEWSON MARILLYN A
12/4
01:26 pm
jnj
Form 144 JOHNSON & JOHNSON Filed by: Hait William
Low
Report
Form 144 JOHNSON & JOHNSON Filed by: Hait William
11/13
04:46 pm
jnj
Form 13F-HR JOHNSON & JOHNSON For: Sep 30
Low
Report
Form 13F-HR JOHNSON & JOHNSON For: Sep 30
11/6
09:24 am
jnj
Form 25-NSE JOHNSON & JOHNSON Filed by: NEW YORK STOCK EXCHANGE LLC
Low
Report
Form 25-NSE JOHNSON & JOHNSON Filed by: NEW YORK STOCK EXCHANGE LLC
10/31
05:58 pm
jnj
Form 4/A JOHNSON & JOHNSON For: May 01 Filed by: REED JOHN C
Low
Report
Form 4/A JOHNSON & JOHNSON For: May 01 Filed by: REED JOHN C
10/23
04:03 pm
jnj
Form 10-Q JOHNSON & JOHNSON For: Sep 29
Low
Report
Form 10-Q JOHNSON & JOHNSON For: Sep 29
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/27
Form DEFA14A JOHNSON & JOHNSON
8.1%
3/12 Paul Harris' Top Picks: March 12, 2020 [Business News Network (BNN) Energy & Resources (Canada)] 7.5%
4/7 Is JNJ Stock A Buy On CEO's Bullish Call For Coronavirus Vaccine? [Investor's Business Daily] 4.6%
4/5 Will These 3 Coronavirus Stocks Lead the Market to Recovery? [Yahoo! Finance News] 4.3%
4/13 Stocks slip as market enters new phase, with investors worrying about balance sheets [CNBC] 4.0%
3/2 AODocs Joins AIIM Leadership Council, Showcases Innovative Approach to Information Management at 2020 AIIM Conference 3.9%
3/4 Johnson & Johnson ordered to pay $1.7 million to three Australian women in pelvic mesh class action [Reuters] 3.8%
3/18 Is This 1 Healthcare Stock Coronavirus-Proof? [The Motley Fool] 3.8%
3/24 What Technology And Manufacturing Can Do To Help Against COVID-19 [Forbes] 3.6%
4/1 5 of the Best Stocks to Buy for April [Yahoo! Finance News] 3.3%
3/12 Paul Harris' Top Picks: March 12, 2020 [Business News Network (BNN) Energy & Resources (Canada)] 7.5%
4/7 Is JNJ Stock A Buy On CEO's Bullish Call For Coronavirus Vaccine? [Investor's Business Daily] 4.6%
4/5 Will These 3 Coronavirus Stocks Lead the Market to Recovery? [Yahoo! Finance News] 4.3%
4/13 Stocks slip as market enters new phase, with investors worrying about balance sheets [CNBC] 4.0%
3/2 AODocs Joins AIIM Leadership Council, Showcases Innovative Approach to Information Management at 2020 AIIM Conference 3.9%
3/4 Johnson & Johnson ordered to pay $1.7 million to three Australian women in pelvic mesh class action [Reuters] 3.8%
3/18 Is This 1 Healthcare Stock Coronavirus-Proof? [The Motley Fool] 3.8%
3/24 What Technology And Manufacturing Can Do To Help Against COVID-19 [Forbes] 3.6%
4/1 5 of the Best Stocks to Buy for April [Yahoo! Finance News] 3.3%
TOP News Decliners
3/21
Johnson and Johnson: A Safe Haven in Recession [The Motley Fool]
-7.3%
3/20 Is Johnson & Johnson (NYSE:JNJ) Trading At A 35% Discount? [Yahoo! Finance News] -6.9%
3/10 J&J MET antibody nabs accelerated review status for certain lung cancer patients [Seeking Alpha] -6.8%
3/18 J&J files U.S. application for MS med ponesimod [Seeking Alpha] -6.6%
10/18 Wolves In Sheep’s Clothing: We Can’t Trust Businesses To Do Right By Americans Now [Forbes] -6.4%
5/28 Oklahoma taking on Johnson & Johnson in historic trial [MSNBC.com] -6.1%
3/13 Americans rush to stock up on essentials as coronavirus spreads [Reuters] -5.5%
3/11 Desperate to exit, a $10B price tag for Magic Leap is crazy [TechCrunch Blog] -4.9%
7/12 Johnson & Johnson (NYSE: JNJ) is now covered by analysts at Credit Suisse Group AG. They set an "outperform" rating and a $156.00 price target on the stock. -4.5%
3/6 Eyecare industry leaders sign Proclamation to focus on key issues facing the future of optometry -3.8%
3/20 Is Johnson & Johnson (NYSE:JNJ) Trading At A 35% Discount? [Yahoo! Finance News] -6.9%
3/10 J&J MET antibody nabs accelerated review status for certain lung cancer patients [Seeking Alpha] -6.8%
3/18 J&J files U.S. application for MS med ponesimod [Seeking Alpha] -6.6%
10/18 Wolves In Sheep’s Clothing: We Can’t Trust Businesses To Do Right By Americans Now [Forbes] -6.4%
5/28 Oklahoma taking on Johnson & Johnson in historic trial [MSNBC.com] -6.1%
3/13 Americans rush to stock up on essentials as coronavirus spreads [Reuters] -5.5%
3/11 Desperate to exit, a $10B price tag for Magic Leap is crazy [TechCrunch Blog] -4.9%
7/12 Johnson & Johnson (NYSE: JNJ) is now covered by analysts at Credit Suisse Group AG. They set an "outperform" rating and a $156.00 price target on the stock. -4.5%
3/6 Eyecare industry leaders sign Proclamation to focus on key issues facing the future of optometry -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: